Dana-Farber and collaborators presented CAR-T outcomes in high-risk smoldering multiple myeloma using Carvykti (ciltacabtagene autoleucel). In the reported phase 2 CAR-PRISM trial, 20 patients with high-risk SMM showed deep responses, including reports that all treated patients had no detectable myeloma cells at assessment. The study aims to test whether CAR-T can prevent progression from precursor disease to active multiple myeloma by intercepting the process earlier than typical treatment. Researchers and external commentary in the update positioned the question as whether this could redefine treatment goals for high-risk SMM beyond delaying progression. If confirmed in larger follow-up, the approach could shift the standard of care for precursor disease and influence how clinicians balance early high-intensity immunotherapy against long-term disease control, especially in patient subgroups with markers of imminent progression.